Nature Communications (Jul 2023)

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma

  • Philip Smith,
  • Thomas Bradley,
  • Lena Morrill Gavarró,
  • Teodora Goranova,
  • Darren P. Ennis,
  • Hasan B. Mirza,
  • Dilrini De Silva,
  • Anna M. Piskorz,
  • Carolin M. Sauer,
  • Sarwah Al-Khalidi,
  • Ionut-Gabriel Funingana,
  • Marika A. V. Reinius,
  • Gaia Giannone,
  • Liz-Anne Lewsley,
  • Jamie Stobo,
  • John McQueen,
  • Gareth Bryson,
  • Matthew Eldridge,
  • The BriTROC Investigators,
  • Geoff Macintyre,
  • Florian Markowetz,
  • James D. Brenton,
  • Iain A. McNeish

DOI
https://doi.org/10.1038/s41467-023-39867-7
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 15

Abstract

Read online

Abstract The drivers of recurrence and resistance in ovarian high grade serous carcinoma remain unclear. We investigate the acquisition of resistance by collecting tumour biopsies from a cohort of 276 women with relapsed ovarian high grade serous carcinoma in the BriTROC-1 study. Panel sequencing shows close concordance between diagnosis and relapse, with only four discordant cases. There is also very strong concordance in copy number between diagnosis and relapse, with no significant difference in purity, ploidy or focal somatic copy number alterations, even when stratified by platinum sensitivity or prior chemotherapy lines. Copy number signatures are strongly correlated with immune cell infiltration, whilst diagnosis samples from patients with primary platinum resistance have increased rates of CCNE1 and KRAS amplification and copy number signature 1 exposure. Our data show that the ovarian high grade serous carcinoma genome is remarkably stable between diagnosis and relapse and acquired chemotherapy resistance does not select for common copy number drivers.